Non-specialty pipeline forecast as of October 2009

[chantell.reagan]

In 4Q09, there are approximately 14 agents awaiting FDA review, in the areas of hypertension, diabetes, osteoarthritis, insomnia, hypogonadism, pain management, restless leg, GERD and excessive sleepiness associated w/ jet lag. The following list represents non-specialty pipeline updates for October 2009 from DrugPipelineForecast. Please click on the product name to view update for individual products. To access DrugPipelineForecast, you must be a registered user of DrugManagementForum (click here to register)

Androxal - positive phase III data (new entry in DrugPipelineForecast)

Axiron - positive phase III data

dapagaflozin - positive phase III data

EV2/DNG - positive phase III data

Exalgo - positive phase III data

Fortesta - Complete response letter received

gabapentin GR (DM-1796) - positive phase III data

indacaterol - Complete response letter received

Intermezzo - FDA rejects drug

Kynapid - positive phase III data

linagliptin - pivotal phase III trials conclude (new entry in DrugPipelineForecast)

lorcaserin - positive phase III data

naproxcinod - NDA submitted

Nuvigil -priority review w/ upcoming PDUFA date

Ophena - positive phase III data

Pancrecarb - Complete response letter received

peramivir - emergency use authorized by FDA

PTK 0796 - broad-spectrum antiinfective in phase III (new entry in DrugPipelineForecast)

Serada - positive phase III data

Victoza - positive phase IIIb data

Vimovo - positive phase III data

Zenvia - positive phase III data

Zunrisa - regulatory filings w/d

For more information, or to search additional drugs, please see DrugPipelineForecast